Publications by authors named "Luz Tarin"
Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.
Cesar Homero Gutiérrez-Aguirre Olga Graciela Cantú-Rodríguez Omar David Borjas-Almaguer Oscar González-Llano José Carlos Jaime-Pérez Luz Tarin
Haematologica
May 2012
Article Synopsis
- Chronic graft-versus-host disease is a common complication after stem cell transplants, often treated initially with corticosteroids, but second-line treatment options are unclear.
- The study involved 15 patients (10 men and 5 women) receiving a combination of low-dose alemtuzumab and rituximab, with results showing a 100% overall response rate at 30 days.
- While the combination therapy was found to be effective and generally safe, with manageable side effects mostly related to infections, further research is needed to assess long-term outcomes and durability of the treatment response.